<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="151672">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01125566</url>
  </required_header>
  <id_info>
    <org_study_id>1200.75</org_study_id>
    <secondary_id>2009-015476-98</secondary_id>
    <nct_id>NCT01125566</nct_id>
  </id_info>
  <brief_title>LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment</brief_title>
  <official_title>LUX-Breast 1; An Open Label, Randomised Phase III Trial of BIBW 2992 and Vinorelbine Versus Trastuzumab and Vinorelbine in Patients With Metastatic HER2-overexpressing Breast Cancer Failing One Prior Trastuzumab Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      To investigate the efficacy and safety of BIBW 2992 in combination with vinorelbine i.v.
      chemotherapy as treatment in patients with HER2-overexpressing, metastatic breast cancer,
      who failed one prior trastuzumab (Herceptin®) treatment
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>From randomization until disease progression, death or data cut-off (08Jun2013); Up to 34 months</time_frame>
    <description>PFS is defined as time from randomisation to disease progression or death whichever occurs first. Assessed by investigator according to the Response Evaluation Criteria in Solid Tumours (RECIST 1.1).
Only data collected until the cut-off date for RECIST 1.1 based endpoints (08Jun2013) were considered.
Progression of disease was determined if at least 1 of the following criteria applied:
At least a 20% increase in the sum of the diameters (SoD) of target lesions taking as reference the smallest SoD recorded since the treatment started, together with an absolute increase in the SoD of at least 5 mm
Appearance of 1 or more new lesions
Unequivocal progression of existing non-target lesions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response (OR)</measure>
    <time_frame>Post baseline tumour-imaging was performed at Week 8, 16, 24, 32, 40, 48, 56 and then every 12 weeks (Up to 34 months)</time_frame>
    <description>OR is defined as complete response (CR) and partial response (PR). Assessed by investigator according to RECIST 1.1.
Only data collected until the cut-off date 08Jun2013 were considered. Complete Response (CR) for target lesions (TL): Disappearance of all target lesions.
Complete Response (CR) for non-target lesions (NTL): Disappearance of all non-target lesions and normalization of tumour marker level. All lymph nodes must be non-pathological in size (&lt;10mm short axis)
Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum diameters.
Other factors which add to the overall response of an imaging timepoint as PR are as below:-
CR in TL, but non-CR/Non-PD in NTL leads to PR
CR in TL, but not evaluated NTL leads to PR
PR in TL, but non-PD NTL or not all evaluated NTL leads to PR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best RECIST Assessment</measure>
    <time_frame>Post baseline tumour-imaging was performed at Week 8, 16, 24, 32, 40, 48, 56 and then every 12 weeks (Data collected until cut-off date 08Jun2013; Up to 34 months)</time_frame>
    <description>Best RECIST assessment is defined as CR, PR, stable disease (SD), PD or not evaluable by investigator (RECIST version 1.1).
CR for target lesions (TL): Disappearance of all target lesions.
CR for non-target lesions (NTL): Disappearance of all non-target lesions and normalization of tumour marker level. All lymph nodes must be non-pathological in size (&lt;10mm short axis).
PR: At least a 30% decrease in the sum of diameters (SoD) of target lesions taking as reference the baseline sum diameters.
SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as references the smallest SoD while on study.
PD: At least a 20% increase in the SoD of target lesions, taking as references the smallest sum on study (this includes the baseline sum if that is the smallest on study). Also, the sum must also demonstrate an absolute increase of a least 5mm. Appearance of one or more new lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>From randomisation to data cut-off (03Sep2013); Up to 37 months.</time_frame>
    <description>OS is defined as time from randomisation to death irrespective of the cause of the death.
For patients who had not died up to the cut-off date (03Sep2013), the date they were last known to be alive was derived from the patient status records, the trial completion record, radiological imaging assessments, the study treatment termination record, and the randomisation date.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">508</enrollment>
  <condition>Breast Neoplasms</condition>
  <arm_group>
    <arm_group_label>Arm B: trastuzumab with vinorelbine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients receive weekly intravenous infusion of trastuzumab and vinorelbine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm A: BIBW 2992 with vinorelbine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients receive BIBW 2992 tablets once daily combined with weekly intravenous infusion of vinorelbine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIBW 2992</intervention_name>
    <description>patients receive BIBW 2992 tablets once daily and can reduce dose for adverse event management</description>
    <arm_group_label>Arm A: BIBW 2992 with vinorelbine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>trastuzumab</intervention_name>
    <description>patients receive trastuzumab 2mg/kg intravenously every week</description>
    <arm_group_label>Arm B: trastuzumab with vinorelbine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vinorelbine</intervention_name>
    <description>patients receive vinorelbine 25mg/m² intravenously every week</description>
    <arm_group_label>Arm B: trastuzumab with vinorelbine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vinorelbine</intervention_name>
    <description>patients receive vinorelbine 25mg/m² intravenously every week</description>
    <arm_group_label>Arm A: BIBW 2992 with vinorelbine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Histologically confirmed diagnosis of HER2-overexpression breast cancer

          -  Stage IV metastatic disease

          -  Must have progressed on one prior trastuzumab treatment

          -  no more than one prior trastuzumab based therapy regimen (either adjuvant or
             first-line)

          -  Must have received anthracycline and/or taxane based chemotherapy for adjuvant
             treatment of breast cancer or first-line treatment of metastatic breast cancer

          -  Must have (archived) tumour tissue sample available for central re-assessment of
             HER2-status

          -  At least one measurable lesion according to RECIST 1.1.

          -  ECOG score of 0 or 1 .

        Exclusion criteria:

          -  Prior treatment with EGFR/HER2-targeted small molecules or antibodies other than
             trastuzumab

          -  Prior treatment with vinorelbine

          -  Known pre-existing interstitial lung disease

          -  Active brain metastases

          -  History or presence of clinically relevant cardiovascular abnormalities such as
             uncontrolled hypertension, congestive heart failure NYHA classification of 3,
             unstable angina or poorly controlled arrhythmia. Myocardial infarction within 6
             months prior to randomisation.

          -  Cardiac left ventricular function with resting ejection fraction of less than 50%.

          -  Patients unable to comply with the protocol.

          -  Any contraindications for therapy with vinorelbine or trastuzumab.

          -  Known hypersensitivity to BIBW 2992 or the excipients of any of the trial drugs.

          -  Use of any investigational drug within 4 weeks of randomisation.

          -  Inadequate hepatic, renal and haematologic organ function
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1200.75.10013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.10051 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.10113 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Alhambra</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.10010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.10112 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.10004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.10109 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Redondo Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.10103 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Santa Barbara</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.10102 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Santa Maria</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.10031 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Skokie</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.10020 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Waterloo</city>
        <state>Iowa</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.10044 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.10110 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.10048 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.10043 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Salt lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.54005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.54001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Capital Federal</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.54010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ciudad Autonoma de Bs As</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.54009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cordoba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.54008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pergamino - Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.54003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Quilmes</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.54004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rosario</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.61002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Port Macquarie</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.61001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fitzroy</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.61007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Frankston</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.61004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ringwood East</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.61006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.43002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Linz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.43001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.37504 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Grodno</city>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.37501 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Minsk region</city>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.37502 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Minsk</city>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.37503 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vitebsk</city>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.32001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.32005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Edegem</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.32003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Liège</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.55003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cachoeiro de Itapemirim</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.55010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Curitiba</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.55012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ijui</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.55019 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pelotas</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.55002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Porto Alegre</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.55005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Porto Alegre</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.55008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Porto Alegre</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.55004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rio de Janeiro</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.55011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Santo André</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.55016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.55020 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.11005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.11002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moncton</city>
        <state>New Brunswick</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.11004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kitchener</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.11006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.11003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.11001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.11007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Quebec</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.56001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Temuco</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.86001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.86002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.86003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.86004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.86005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.86008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Changchun</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.86021 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chengdu</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.86019 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fuzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.86016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.86017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.86018 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.86022 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Haerbin</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.86012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.86013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.86015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jinan</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.86011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nanjing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.86009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.86010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.86006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tianjin</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.86020 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wuhan</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.42004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ceske Budejovice</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.42003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Olomouc</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.42001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Prague 2</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.42002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Praha 4</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.20003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.20001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mansoura</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.33020 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Amiens Cedex 1</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.33011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Angers Cedex 9</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.33007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Besançon Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.33009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.33006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Clermont-Ferrand Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.33014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Le Mans</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.33013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.33012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.33001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.33016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rennes Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.33021 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St Cloud</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.33008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Strasbourg Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.49004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aachen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.49013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.49026 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bottrop</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.49002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Deggendorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.49009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Erlangen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.49021 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.49008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hildesheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.49001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Köln</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.49006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Köln</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.49014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Magdeburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.49007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.49025 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.49011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oldenburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.49012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rostock</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.49024 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wuppertal</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.91010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Amravati</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.91001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bangalore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.91017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chennai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.91011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hyderabad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.91009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kolkata</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.91013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nagpur</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.91006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nashik</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.91004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pune</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.91022 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pune</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.91005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Visakhapatnam</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.35307 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dubliin 9</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.35301 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dublin 4</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.35303 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dublin 7</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.35306 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dublin 7</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.35302 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dublin 8</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.35305 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Galway</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.35304 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Limerick</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.97203 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.97205 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.97210 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kfar Saba</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.97201 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tel Hashomer</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.97206 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tel-Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.39008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ferrara</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.39001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.39007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Monserrato (CA)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.81005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chuo-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.81013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Higashinari-ku, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.81008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Isehara-shi, Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.82001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Goyang</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.82002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.82003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.82004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.82005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.82006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.37101 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.37102 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.96101 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lebanon</city>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.37001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kaunas</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.37002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vilnius</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.52003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Colonia Centro</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.52006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Luis Potosi</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.31003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dordrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.31004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Eindhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.31001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Geleen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.31006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Heerlen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.31005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.31009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Zwolle</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.51007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Arequipa</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.51004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cusco</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.51005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.51002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Miraflores</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.51001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Isidro</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.51006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Trujillo</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.48002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bialystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.48006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bytom</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.48003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gdansk</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.48004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.48007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.48001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Olsztyn</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.48013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Poznan</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.48010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.35102 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Coimbra</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.35104 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Coimbra</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.35101 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lisboa</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.35103 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Porto</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.35110 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Porto</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.07006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kazan</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.07008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.07011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ryazan</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.07001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.65001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.65002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.65003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.42103 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bardejov</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.42102 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.42104 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Poprad</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.38601 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ljubljana</city>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.27001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Johannesburg</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.27006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Johannesburg</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.27004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kraaifontein</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.27005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Port Elizabeth</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.27008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rondebosch, Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.34001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.34002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.34011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.34004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Las Palmas de Gran Canaria</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.34007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.34009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Santiago de Compostela</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.34005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toledo</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.34008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.94001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Maharagama</city>
        <country>Sri Lanka</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.88607 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Changhua</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.88604 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.88608 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.88602 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.88609 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tainan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.88601 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.88603 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.88606 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.88610 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.88605 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taoyuan County</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.90002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.90001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Izmir</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.44002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dundee</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.44003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Edinburgh</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.44001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.44007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.44006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sutton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.75.44005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Woolwich, London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belarus</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>China</country>
    <country>Czech Republic</country>
    <country>Egypt</country>
    <country>France</country>
    <country>Germany</country>
    <country>India</country>
    <country>Ireland</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Latvia</country>
    <country>Lebanon</country>
    <country>Lithuania</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Peru</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Russian Federation</country>
    <country>Singapore</country>
    <country>Slovakia</country>
    <country>Slovenia</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sri Lanka</country>
    <country>Taiwan</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Colombia</country>
    <country>Croatia</country>
    <country>Finland</country>
    <country>Jordan</country>
    <country>Norway</country>
    <country>Saudi Arabia</country>
    <country>United Arab Emirates</country>
  </removed_countries>
  <verification_date>August 2016</verification_date>
  <lastchanged_date>August 22, 2016</lastchanged_date>
  <firstreceived_date>May 10, 2010</firstreceived_date>
  <firstreceived_results_date>June 6, 2014</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vinorelbine</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Vinblastine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Afatinib+ Vinorelbine (AV)</title>
          <description>Patients received continuous daily treatment with afatinib at a starting dose of 40 mg once daily and weekly infusions of vinorelbine (25mg/m^2). The treatment was administered in treatment courses of 28 days. For afatinib, a protocol- defined dose-reduction scheme was to be followed if a patient experienced certain pre-specified adverse events. All patients without disease progression who were on treatment on 26Apr2013 had to immediately discontinue Afatinib+ Vinorelbine combination treatment. Patients in this group could continue with either vinorelbine or afatinib monotherapy if they experienced clinical benefit.</description>
        </group>
        <group group_id="P2">
          <title>Trastuzumab+ Vinorelbine (TV)</title>
          <description>Patients received weekly infusion of Trastuzumab (2 mg/ kg, following an initial loading dose of 4 mg/ kg) and weekly infusions of vinorelbine (25mg/m^2). The treatment was administered in treatment courses of 28 days.</description>
        </group>
        <group group_id="P3">
          <title>AV Switched to TV</title>
          <description>This group describes patients who crossed over from AV to TV following DMC recommendation to terminate recruitment on 26Apr2013. Patients discontinued AV and switched to TV if they were without disease progression on Afatinib+ Vinorelbine treatment on 26Apr2013.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Patients Before the Switch (26Apr2013)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="339">Randomised</participants>
                <participants group_id="P2" count="169">Randomised</participants>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="79">All patients without disease progression who were on treatment on 08Jun2013</participants>
                <participants group_id="P2" count="33">On treatment at analysis cut-off date (03Sep2013)</participants>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="260"/>
                <participants group_id="P2" count="136"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Progressive disease according to RECIST</title>
              <participants_list>
                <participants group_id="P1" count="181"/>
                <participants group_id="P2" count="100"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Worsening of underlying cancer disease</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Refused to continue taking medication</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not treated</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other than those stated above</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Patients Who Switched From AV to TV</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="73">All patients without disease progression who chose to switch from AV to TV by 08Jun2013</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="49">On TV treatment at analysis cut-off date (03Sep2013)</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="24"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Progressive disease according to RECIST</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="20"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Refused to continue taking medication</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Treated Set :The treated set included all randomised patients who were documented to have taken at least 1 dose of study medication (One centre was excluded from analysis due to serious non-compliance, thus data from 5 patients in AV arm and 1 patient in TV arm were excluded)</population>
      <group_list>
        <group group_id="B1">
          <title>Afatinib + Vinorelbine (AV)</title>
          <description>Patients received continuous daily treatment with afatinib at a starting dose of 40 mg once daily and weekly infusions of vinorelbine (25mg/m^2). The treatment was administered in treatment courses of 28 days. For afatinib, a protocol- defined dose-reduction scheme was to be followed if a patient experienced certain pre-specified adverse events. All patients without disease progression who were on treatment on 26Apr2013 had to immediately discontinue Afatinib+ Vinorelbine combination treatment. Patients in this group could continue with either vinorelbine or afatinib monotherapy if they experienced clinical benefit.</description>
        </group>
        <group group_id="B2">
          <title>Trastuzumab + Vinorelbine (TV)</title>
          <description>Patients received weekly infusion of Trastuzumab (2 mg/ kg, following an initial loading dose of 4 mg/ kg) and weekly infusions of vinorelbine (25mg/m^2). The treatment was administered in treatment courses of 28 days.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="332"/>
            <count group_id="B2" value="168"/>
            <count group_id="B3" value="500"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.8" spread="11.3"/>
                    <measurement group_id="B2" value="53.1" spread="12.3"/>
                    <measurement group_id="B3" value="52.2" spread="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="332"/>
                    <measurement group_id="B2" value="168"/>
                    <measurement group_id="B3" value="500"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression-free Survival (PFS)</title>
        <description>PFS is defined as time from randomisation to disease progression or death whichever occurs first. Assessed by investigator according to the Response Evaluation Criteria in Solid Tumours (RECIST 1.1).
Only data collected until the cut-off date for RECIST 1.1 based endpoints (08Jun2013) were considered.
Progression of disease was determined if at least 1 of the following criteria applied:
At least a 20% increase in the sum of the diameters (SoD) of target lesions taking as reference the smallest SoD recorded since the treatment started, together with an absolute increase in the SoD of at least 5 mm
Appearance of 1 or more new lesions
Unequivocal progression of existing non-target lesions</description>
        <time_frame>From randomization until disease progression, death or data cut-off (08Jun2013); Up to 34 months</time_frame>
        <population>Randomised set (RS): The randomised set included all patients who were randomised to receive treatment, whether treated or not</population>
        <group_list>
          <group group_id="O1">
            <title>Afatinib+ Vinorelbine (AV)</title>
            <description>Patients received continuous daily treatment with afatinib at a starting dose of 40 mg once daily and weekly infusions of vinorelbine (25mg/m^2). The treatment was administered in treatment courses of 28 days. For afatinib, a protocol- defined dose-reduction scheme was to be followed if a patient experienced certain pre-specified adverse events. All patients without disease progression who were on treatment on 26Apr2013 had to immediately discontinue Afatinib+ Vinorelbine combination treatment. Patients in this group could continue with either vinorelbine or afatinib monotherapy if they experienced clinical benefit.</description>
          </group>
          <group group_id="O2">
            <title>Trastuzumab+ Vinorelbine (TV)</title>
            <description>Patients received weekly infusion of Trastuzumab (2 mg/ kg, following an initial loading dose of 4 mg/ kg) and weekly infusions of vinorelbine (25mg/m^2). The treatment was administered in treatment courses of 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival (PFS)</title>
          <description>PFS is defined as time from randomisation to disease progression or death whichever occurs first. Assessed by investigator according to the Response Evaluation Criteria in Solid Tumours (RECIST 1.1).
Only data collected until the cut-off date for RECIST 1.1 based endpoints (08Jun2013) were considered.
Progression of disease was determined if at least 1 of the following criteria applied:
At least a 20% increase in the sum of the diameters (SoD) of target lesions taking as reference the smallest SoD recorded since the treatment started, together with an absolute increase in the SoD of at least 5 mm
Appearance of 1 or more new lesions
Unequivocal progression of existing non-target lesions</description>
          <population>Randomised set (RS): The randomised set included all patients who were randomised to receive treatment, whether treated or not</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="339"/>
                <count group_id="O2" value="169"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.49" lower_limit="3.55" upper_limit="9.03"/>
                    <measurement group_id="O2" value="5.55" lower_limit="3.55" upper_limit="10.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4272</p_value>
            <p_value_desc>Two sided p-value from a log rank test stratified by the setting of prior Trastuzumab failure, hormone receptors status and region of the investigational site</p_value_desc>
            <method>Regression, Cox</method>
            <method_desc>Cox proportional hazard (PH) regression stratified by prior Trastuzumab failure, hormone receptors status and region of the investigational site.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.86</ci_lower_limit>
            <ci_upper_limit>1.41</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Objective Response (OR)</title>
        <description>OR is defined as complete response (CR) and partial response (PR). Assessed by investigator according to RECIST 1.1.
Only data collected until the cut-off date 08Jun2013 were considered. Complete Response (CR) for target lesions (TL): Disappearance of all target lesions.
Complete Response (CR) for non-target lesions (NTL): Disappearance of all non-target lesions and normalization of tumour marker level. All lymph nodes must be non-pathological in size (&lt;10mm short axis)
Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum diameters.
Other factors which add to the overall response of an imaging timepoint as PR are as below:-
CR in TL, but non-CR/Non-PD in NTL leads to PR
CR in TL, but not evaluated NTL leads to PR
PR in TL, but non-PD NTL or not all evaluated NTL leads to PR</description>
        <time_frame>Post baseline tumour-imaging was performed at Week 8, 16, 24, 32, 40, 48, 56 and then every 12 weeks (Up to 34 months)</time_frame>
        <population>Randomised set (RS): The randomised set included all patients who were randomised to receive treatment, whether treated or not (One centre was excluded from analysis due to serious non-compliance, thus data from 5 patients in AV arm and 1 patient in TV arm were excluded)</population>
        <group_list>
          <group group_id="O1">
            <title>Afatinib+ Vinorelbine (AV)</title>
            <description>Patients received continuous daily treatment with afatinib at a starting dose of 40 mg once daily and weekly infusions of vinorelbine (25mg/m^2). The treatment was administered in treatment courses of 28 days. For afatinib, a protocol- defined dose-reduction scheme was to be followed if a patient experienced certain pre-specified adverse events. All patients without disease progression who were on treatment on 26Apr2013 had to immediately discontinue Afatinib+ Vinorelbine combination treatment. Patients in this group could continue with either vinorelbine or afatinib monotherapy if they experienced clinical benefit.</description>
          </group>
          <group group_id="O2">
            <title>Trastuzumab+ Vinorelbine (TV)</title>
            <description>Patients received weekly infusion of Trastuzumab (2 mg/ kg, following an initial loading dose of 4 mg/ kg) and weekly infusions of vinorelbine (25mg/m^2). The treatment was administered in treatment courses of 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response (OR)</title>
          <description>OR is defined as complete response (CR) and partial response (PR). Assessed by investigator according to RECIST 1.1.
Only data collected until the cut-off date 08Jun2013 were considered. Complete Response (CR) for target lesions (TL): Disappearance of all target lesions.
Complete Response (CR) for non-target lesions (NTL): Disappearance of all non-target lesions and normalization of tumour marker level. All lymph nodes must be non-pathological in size (&lt;10mm short axis)
Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum diameters.
Other factors which add to the overall response of an imaging timepoint as PR are as below:-
CR in TL, but non-CR/Non-PD in NTL leads to PR
CR in TL, but not evaluated NTL leads to PR
PR in TL, but non-PD NTL or not all evaluated NTL leads to PR</description>
          <population>Randomised set (RS): The randomised set included all patients who were randomised to receive treatment, whether treated or not (One centre was excluded from analysis due to serious non-compliance, thus data from 5 patients in AV arm and 1 patient in TV arm were excluded)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="334"/>
                <count group_id="O2" value="168"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.1" lower_limit="40.7" upper_limit="51.6"/>
                    <measurement group_id="O2" value="47.0" lower_limit="39.3" upper_limit="54.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Results of presented analyses are to be seen as exploratory (no confirmatory testing was performed)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8510</p_value>
            <p_value_desc>Two sided p-value from a log rank test stratified by the setting of prior Trastuzumab failure, hormone receptors status and region of the investigational site</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>Logistic regression stratified for prior Trastuzumab failure, hormone receptors status and region of the investigational site.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.037</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.712</ci_lower_limit>
            <ci_upper_limit>1.508</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Best RECIST Assessment</title>
        <description>Best RECIST assessment is defined as CR, PR, stable disease (SD), PD or not evaluable by investigator (RECIST version 1.1).
CR for target lesions (TL): Disappearance of all target lesions.
CR for non-target lesions (NTL): Disappearance of all non-target lesions and normalization of tumour marker level. All lymph nodes must be non-pathological in size (&lt;10mm short axis).
PR: At least a 30% decrease in the sum of diameters (SoD) of target lesions taking as reference the baseline sum diameters.
SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as references the smallest SoD while on study.
PD: At least a 20% increase in the SoD of target lesions, taking as references the smallest sum on study (this includes the baseline sum if that is the smallest on study). Also, the sum must also demonstrate an absolute increase of a least 5mm. Appearance of one or more new lesions.</description>
        <time_frame>Post baseline tumour-imaging was performed at Week 8, 16, 24, 32, 40, 48, 56 and then every 12 weeks (Data collected until cut-off date 08Jun2013; Up to 34 months)</time_frame>
        <population>Randomised set (RS): The randomised set included all patients who were randomised to receive treatment, whether treated or not (One centre was excluded from analysis due to serious non-compliance, thus data from 5 patients in AV arm and 1 patient in TV arm were excluded)</population>
        <group_list>
          <group group_id="O1">
            <title>Afatinib+ Vinorelbine (AV)</title>
            <description>Patients received continuous daily treatment with afatinib at a starting dose of 40 mg once daily and weekly infusions of vinorelbine (25mg/m^2). The treatment was administered in treatment courses of 28 days. For afatinib, a protocol- defined dose-reduction scheme was to be followed if a patient experienced certain pre-specified adverse events. All patients without disease progression who were on treatment on 26Apr2013 had to immediately discontinue Afatinib+ Vinorelbine combination treatment. Patients in this group could continue with either vinorelbine or afatinib monotherapy if they experienced clinical benefit.</description>
          </group>
          <group group_id="O2">
            <title>Trastuzumab+ Vinorelbine (TV)</title>
            <description>Patients received weekly infusion of Trastuzumab (2 mg/ kg, following an initial loading dose of 4 mg/ kg) and weekly infusions of vinorelbine (25mg/m^2). The treatment was administered in treatment courses of 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Best RECIST Assessment</title>
          <description>Best RECIST assessment is defined as CR, PR, stable disease (SD), PD or not evaluable by investigator (RECIST version 1.1).
CR for target lesions (TL): Disappearance of all target lesions.
CR for non-target lesions (NTL): Disappearance of all non-target lesions and normalization of tumour marker level. All lymph nodes must be non-pathological in size (&lt;10mm short axis).
PR: At least a 30% decrease in the sum of diameters (SoD) of target lesions taking as reference the baseline sum diameters.
SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as references the smallest SoD while on study.
PD: At least a 20% increase in the SoD of target lesions, taking as references the smallest sum on study (this includes the baseline sum if that is the smallest on study). Also, the sum must also demonstrate an absolute increase of a least 5mm. Appearance of one or more new lesions.</description>
          <population>Randomised set (RS): The randomised set included all patients who were randomised to receive treatment, whether treated or not (One centre was excluded from analysis due to serious non-compliance, thus data from 5 patients in AV arm and 1 patient in TV arm were excluded)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="334"/>
                <count group_id="O2" value="168"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete response (CR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2"/>
                    <measurement group_id="O2" value="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial response (PR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.9"/>
                    <measurement group_id="O2" value="44.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable disease (SD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.7"/>
                    <measurement group_id="O2" value="27.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressive Disease (PD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.3"/>
                    <measurement group_id="O2" value="17.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not evaluable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.6"/>
                    <measurement group_id="O2" value="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Results of presented analyses are to be seen as exploratory (no confirmatory testing was performed)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6569</p_value>
            <p_value_desc>Two sided p-value from a log rank test stratified by the setting of prior Trastuzumab failure, hormone receptors status and region of the investigational site</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>Logistic regression stratified for prior Trastuzumab failure, hormone receptors status and region of the investigational site.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.086</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.754</ci_lower_limit>
            <ci_upper_limit>1.565</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS)</title>
        <description>OS is defined as time from randomisation to death irrespective of the cause of the death.
For patients who had not died up to the cut-off date (03Sep2013), the date they were last known to be alive was derived from the patient status records, the trial completion record, radiological imaging assessments, the study treatment termination record, and the randomisation date.</description>
        <time_frame>From randomisation to data cut-off (03Sep2013); Up to 37 months.</time_frame>
        <population>Randomised set (RS): The randomised set included all patients who were randomised to receive treatment, whether treated or not</population>
        <group_list>
          <group group_id="O1">
            <title>Afatinib+ Vinorelbine (AV)</title>
            <description>Patients received continuous daily treatment with afatinib at a starting dose of 40 mg once daily and weekly infusions of vinorelbine (25mg/m^2). The treatment was administered in treatment courses of 28 days. For afatinib, a protocol- defined dose-reduction scheme was to be followed if a patient experienced certain pre-specified adverse events. All patients without disease progression who were on treatment on 26Apr2013 had to immediately discontinue Afatinib+ Vinorelbine combination treatment. Patients in this group could continue with either vinorelbine or afatinib monotherapy if they experienced clinical benefit.</description>
          </group>
          <group group_id="O2">
            <title>Trastuzumab+ Vinorelbine (TV)</title>
            <description>Patients received weekly infusion of Trastuzumab (2 mg/ kg, following an initial loading dose of 4 mg/ kg) and weekly infusions of vinorelbine (25mg/m^2). The treatment was administered in treatment courses of 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <description>OS is defined as time from randomisation to death irrespective of the cause of the death.
For patients who had not died up to the cut-off date (03Sep2013), the date they were last known to be alive was derived from the patient status records, the trial completion record, radiological imaging assessments, the study treatment termination record, and the randomisation date.</description>
          <population>Randomised set (RS): The randomised set included all patients who were randomised to receive treatment, whether treated or not</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="339"/>
                <count group_id="O2" value="169"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.58" lower_limit="10.64">Not calculable due to small number of patients who died during the trial.</measurement>
                    <measurement group_id="O2" value="28.62" lower_limit="14.62">Not calculable due to small number of patients who died during the trial.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Results of presented analyses are to be seen as exploratory (no confirmatory testing was performed)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0036</p_value>
            <p_value_desc>Two sided p-value from a log rank test stratified by the setting of prior Trastuzumab failure, hormone receptors status and region of the investigational site</p_value_desc>
            <method>Regression, Cox</method>
            <method_desc>Cox proportional hazard (PH) regression stratified by the prior Trastuzumab failure, hormone receptors status and region of the investigational site.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.76</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.20</ci_lower_limit>
            <ci_upper_limit>2.59</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first administration of treatment within the trial until 28 days after last administration of treatment within the trial, up to 869 days.</time_frame>
      <desc>For the AV group, in the participant flow &quot;Total participants (Started)&quot; are 339 and for Adverse events &quot;Total # participants affected at risk&quot; are 337, this is because out of 339 subjects from the AV group, 2 subjects were not treated with the treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Afatinib+ Vinorelbine (AV)</title>
          <description>Patients received continuous daily treatment with afatinib at a starting dose of 40 mg once daily and weekly infusions of vinorelbine (25mg/m^2). The treatment was administered in treatment courses of 28 days. For afatinib, a protocol- defined dose-reduction scheme was to be followed if a patient experienced certain pre-specified adverse events. All patients without disease progression who were on treatment on 26Apr2013 had to immediately discontinue Afatinib+ Vinorelbine combination treatment. Patients in this group could continue with either vinorelbine or afatinib monotherapy if they experienced clinical benefit.</description>
        </group>
        <group group_id="E2">
          <title>Trastuzumab+ Vinorelbine (TV)</title>
          <description>Patients received weekly infusion of Trastuzumab (2 mg/ kg, following an initial loading dose of 4 mg/ kg) and weekly infusions of vinorelbine (25mg/m^2). The treatment was administered in treatment courses of 28 days.</description>
        </group>
        <group group_id="E3">
          <title>AV Switched to TV</title>
          <description>This group describes patients who crossed over from AV to TV following DMC recommendation to terminate recruitment on 26Apr2013. Patients discontinued AV and switched to TV if they were without disease progression on Afatinib+ Vinorelbine treatment on 26Apr2013.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="122" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Agranulocytosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Bone marrow failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Keratitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Acute abdomen</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Gastroduodenitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Haemorrhagic ascites</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Adverse drug reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Condition aggravated</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Disease progression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Facial pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Multi-organ disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Thrombosis in device</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Abscess intestinal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Atypical pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Cardiac infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Catheter site infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Genital infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Hepatitis B</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Lymphangitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Pulmonary sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Viraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod sting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Blood urea increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Intervertebral disc disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Brain cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Brain neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Breast cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Breast cancer recurrent</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Infected neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm progression</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Malignant pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Metastases to bone</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Metastases to lung</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Metastases to meninges</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Metastatic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Neoplasm progression</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Pericardial effusion malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Tumour necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Altered state of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Central nervous system lesion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Gliosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Grand mal convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Hepatic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Intracranial pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Paraparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mood altered</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Neurogenic bladder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Breast pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Pulmonary fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Breast operation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Central venous catheterisation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Muscle operation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Venous thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="330" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="160" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="57" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="101" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="114" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="67" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="242" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="133" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="39" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="256" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="99" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="87" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="76" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="104" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="79" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="98" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Dermatitis acneiform</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Palmar-plantar erythrodysaesthesia syndrome</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="159" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI’s intellectual property rights.&gt;</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The Data Monitoring Committee recommended termination of recruitment due to low likelihood of the study meeting its primary objectives.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
